Aesthetic surgery journal
-
Aesthetic surgery journal · Nov 2009
An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
A new formulation of a botulinum neurotoxin type A (BoNTA-ABO; Dysport [abobotulinumtoxinA]; Medicis Aesthetics, Scottsdale, AZ) was recently approved by the US Food and Drug Administration for the treatment of moderate to severe glabellar lines. ⋯ Treatment of glabellar lines with BoNTA-ABO is well tolerated. Overall, the safety profile of BoNTA-ABO is comparable to that of placebo in terms of type, frequency, severity, and relatedness of AE.